Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ACACA | Q13085 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358519 | 0.84 | POLB (0.56) | ACACBPOLBKDM4ENPC1RAB9A | |
| SCHEMBL5355499 | 0.81 | KDM4E (0.49) | ACACBPOLBKDM4ENPC1RAB9A | |
| SCHEMBL21445743 | 0.80 | POLB (0.55) | ACACBPOLBKDM4ENPC1RAB9A | |
| SCHEMBL28749624 | 0.79 | LMNA (0.57) | ACACBNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL7056381 | 0.78 | TSHR (0.53) | NPC1RAB9AALDH1A1KMT2AMAPT | |
| SCHEMBL7058164 | 0.78 | SMN1; SMN2 (0.54) | POLBALDH1A1KMT2AGLA | |
| SCHEMBL12646737 | 0.78 | KDM4E (0.62) | ACACBPOLBKDM4ENPC1RAB9A | |
| SCHEMBL22444651 | 0.76 | KDM4E (0.53) | ACACBPOLBKDM4EACACANPC1 | |
| SCHEMBL18606675 | 0.76 | KDM4E (0.53) | ACACBPOLBKDM4EACACANPC1 | |
| SCHEMBL6964493 | 0.76 | POLB (0.50) | ACACBPOLBKDM4EACACANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| EP-1181294-B1 | NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2004-03-31 | — | — | EP | disclosed |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2003-10-23 | — | — | US | disclosed |
| EP-1181294-A1 | NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN | Sanochemia Pharmazeutika Aktiengesellschaft (AT) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001074820-A1 | NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027138-A1 | Derivatives and analogs of galanthamine | GALR2, GALR1, GALR3 | ACACB 3312/4885POLB 4093/4885KDM4E 3636/4885 |
| US-20030199493-A1 | Novel derivatives and analogues of galanthamin | GALR1, GALNT1, GALK1 | ACACB 1730/4885POLB 3439/4885KDM4E 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.